These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

285 related items for PubMed ID: 16123721

  • 1. Induction therapy for pediatric and adult heart transplantation: comparison between OKT3 and daclizumab.
    Chin C, Pittson S, Luikart H, Bernstein D, Robbins R, Reitz B, Oyer P, Valantine H.
    Transplantation; 2005 Aug 27; 80(4):477-81. PubMed ID: 16123721
    [Abstract] [Full Text] [Related]

  • 2. Experience with single-dose daclizumab in the prevention of acute rejection in heart transplantation.
    Cuppoletti A, Perez-Villa F, Vallejos I, Roig E.
    Transplant Proc; 2005 Nov 27; 37(9):4036-8. PubMed ID: 16386620
    [Abstract] [Full Text] [Related]

  • 3. Daclizumab induction, tacrolimus, mycophenolate mofetil and steroids as an immunosuppression regimen for primary kidney transplant recipients.
    Ciancio G, Burke GW, Suzart K, Roth D, Kupin W, Rosen A, Olson L, Esquenazi V, Miller J.
    Transplantation; 2002 Apr 15; 73(7):1100-6. PubMed ID: 11965039
    [Abstract] [Full Text] [Related]

  • 4. Induction therapy in lung transplantation: a prospective, controlled clinical trial comparing OKT3, anti-thymocyte globulin, and daclizumab.
    Brock MV, Borja MC, Ferber L, Orens JB, Anzcek RA, Krishnan J, Yang SC, Conte JV.
    J Heart Lung Transplant; 2001 Dec 15; 20(12):1282-90. PubMed ID: 11744411
    [Abstract] [Full Text] [Related]

  • 5. Immunosuppressive T-cell antibody induction for heart transplant recipients.
    Penninga L, Møller CH, Gustafsson F, Gluud C, Steinbrüchel DA.
    Cochrane Database Syst Rev; 2013 Dec 02; (12):CD008842. PubMed ID: 24297433
    [Abstract] [Full Text] [Related]

  • 6. Use of daclizumab as initial immunosuppression in liver transplant recipients with impaired renal function.
    Emre S, Gondolesi G, Polat K, Ben-Haim M, Artis T, Fishbein TM, Sheiner PA, Kim-Schluger L, Schwartz ME, Miller CM.
    Liver Transpl; 2001 Mar 02; 7(3):220-5. PubMed ID: 11244163
    [Abstract] [Full Text] [Related]

  • 7. Anti-interleukin-2 receptor antibodies for the prevention of rejection in pediatric renal transplant patients: current status.
    Swiatecka-Urban A.
    Paediatr Drugs; 2003 Mar 02; 5(10):699-716. PubMed ID: 14510627
    [Abstract] [Full Text] [Related]

  • 8. Daclizumab (humanized anti-IL2Ralpha mAb) prophylaxis for prevention of acute rejection in renal transplant recipients with delayed graft function.
    Bumgardner GL, Ramos E, Lin A, Vincenti F, Daclizumab Triple Therapy and Double Therapy Groups.
    Transplantation; 2001 Aug 27; 72(4):642-7. PubMed ID: 11544424
    [Abstract] [Full Text] [Related]

  • 9. Thymoglobulin induction decreases rejection in solitary pancreas transplantation.
    Stegall MD, Kim DY, Prieto M, Cohen AJ, Griffin MD, Schwab TR, Nyberg SL, Velosa JA, Gloor JM, Innocenti F, Bohorquez H, Dean PG, Carpenter HA, Leontovich ON, Sterioff S, Larson TS.
    Transplantation; 2001 Nov 27; 72(10):1671-5. PubMed ID: 11726830
    [Abstract] [Full Text] [Related]

  • 10. Antibody induction therapy for lung transplant recipients.
    Penninga L, Møller CH, Penninga EI, Iversen M, Gluud C, Steinbrüchel DA.
    Cochrane Database Syst Rev; 2013 Nov 27; 2013(11):CD008927. PubMed ID: 24282128
    [Abstract] [Full Text] [Related]

  • 11. Infectious and non-infectious neurologic complications in heart transplant recipients.
    Muñoz P, Valerio M, Palomo J, Fernández-Yáñez J, Fernández-Cruz A, Guinea J, Bouza E.
    Medicine (Baltimore); 2010 May 27; 89(3):166-175. PubMed ID: 20453603
    [Abstract] [Full Text] [Related]

  • 12. Daclizumab to prevent rejection after cardiac transplantation.
    Hershberger RE, Starling RC, Eisen HJ, Bergh CH, Kormos RL, Love RB, Van Bakel A, Gordon RD, Popat R, Cockey L, Mamelok RD.
    N Engl J Med; 2005 Jun 30; 352(26):2705-13. PubMed ID: 15987919
    [Abstract] [Full Text] [Related]

  • 13. Early experience with two-dose daclizumab in the prevention of acute rejection in cardiac transplantation.
    Joyal D, Cantarovich M, Cecere R, Giannetti N.
    Clin Transplant; 2004 Oct 30; 18(5):493-6. PubMed ID: 15344949
    [Abstract] [Full Text] [Related]

  • 14. Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group.
    Nashan B, Light S, Hardie IR, Lin A, Johnson JR.
    Transplantation; 1999 Jan 15; 67(1):110-5. PubMed ID: 9921806
    [Abstract] [Full Text] [Related]

  • 15. A comparison of daclizumab to ATGAM induction in simultaneous pancreas-kidney transplant recipients on triple maintenance immunosuppression.
    Rasaiah SB, Light JA, Sasaki TM, Currier CB.
    Clin Transplant; 2000 Aug 15; 14(4 Pt 2):409-12. PubMed ID: 10946780
    [Abstract] [Full Text] [Related]

  • 16. Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal transplantation: a prospective, randomized study.
    Kandus A, Arnol M, Omahen K, Oblak M, Vidan-Jeras B, Kmetec A, Bren AF.
    Transplantation; 2010 Apr 27; 89(8):1022-7. PubMed ID: 20075788
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Promising early outcomes with a novel, complete steroid avoidance immunosuppression protocol in pediatric renal transplantation.
    Sarwal MM, Yorgin PD, Alexander S, Millan MT, Belson A, Belanger N, Granucci L, Major C, Costaglio C, Sanchez J, Orlandi P, Salvatierra O.
    Transplantation; 2001 Jul 15; 72(1):13-21. PubMed ID: 11468528
    [Abstract] [Full Text] [Related]

  • 19. A randomized prospective trial of low-dose OKT3 induction therapy to prevent rejection and minimize side effects in recipients of kidney transplants.
    Flechner SM, Goldfarb DA, Fairchild R, Modlin CS, Fisher R, Mastroianni B, Boparai N, O'Malley KJ, Cook DJ, Novick AC.
    Transplantation; 2000 Jun 15; 69(11):2374-81. PubMed ID: 10868643
    [Abstract] [Full Text] [Related]

  • 20. Continued superior outcomes with modification and lengthened follow-up of a steroid-avoidance pilot with extended daclizumab induction in pediatric renal transplantation.
    Sarwal MM, Vidhun JR, Alexander SR, Satterwhite T, Millan M, Salvatierra O.
    Transplantation; 2003 Nov 15; 76(9):1331-9. PubMed ID: 14627912
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.